Patent classifications
C09C1/62
Biological inks and coatings and associated methods
The disclosed method and related systems and devices relate to producing a pigment from microbial biomass. The pigment may be an engineered black pigment. The method may include a thermal processing step where the microbial biomass is charred. The biomass in the charred and pre-charred state can be washed chemically and/or mechanically. In another step the biomass is ground via a grinding of milling process. The grinding/milling may occur at any various points in the process. In some embodiments the biomass has a particle size between 0.01 and 100 microns.
EFFECT PIGMENT, MANUFACTURING METHOD, VALUABLE DOCUMENT AND PRINTING INK
A platelet-shaped magnetic effect pigment for use in a printing ink, includes a layer construction with a magnetic layer and at least one optical functional layer. The magnetic layer is based on magnetic particles fixed within a solid matrix and having a largely uniform preferential magnetic direction deviating from the platelet plane.
EFFECT PIGMENT, MANUFACTURING METHOD, VALUABLE DOCUMENT AND PRINTING INK
A platelet-shaped magnetic effect pigment for use in a printing ink, includes a layer construction with a magnetic layer and at least one optical functional layer. The magnetic layer is based on magnetic particles fixed within a solid matrix and having a largely uniform preferential magnetic direction deviating from the platelet plane.
Effect pigments coated with organic binders for powders paints, and a method for producing said coated effect pigments and their use
The invention relates to coated effect pigments, wherein the coating comprises a binder which is suitable for powder paints. They comprise a crystalline and an amorphous fraction which is determined by C.sup.13 NMR MAS relaxation measurements, the relaxation of the .sup.13C cores being fitted as a biexponential relaxation according to the formula (II) and the degree of crystallinity c being in a range between 40 to 85%, and relaxation having a short average relaxation time T.sub.1.sup.S and a long average relaxation time T.sub.1.sup.l, and T.sub.1.sup.l being in a range of from 65 to 130 s. The effect pigments coated according to the invention have at least one endothermic peak with a maximum from a range of T.sub.max=100 to 150° C. and an enthalpy ΔH associated with said peak from a range of 15 J/g to 80 J/g in DSC at a feed speed of 5° C./min, the enthalpy being calculated relative to the amount of the binder. The binders are applied to the effect pigment by way of spontaneous precipitation.
Interference pigment
A multilayered interference pigment containing, in succession: a metal core in the form of a flake, the metal core containing a material selected from gold, silver, palladium, rhodium, ruthenium, platinum, osmium, iridium and an alloy thereof; a first layer of transparent dielectric material; and a second discontinuous metal layer making it possible to both reflect a portion of the light beam and to transmit another portion of this beam onto the metal core.
Interference pigment
A multilayered interference pigment containing, in succession: a metal core in the form of a flake, the metal core containing a material selected from gold, silver, palladium, rhodium, ruthenium, platinum, osmium, iridium and an alloy thereof; a first layer of transparent dielectric material; and a second discontinuous metal layer making it possible to both reflect a portion of the light beam and to transmit another portion of this beam onto the metal core.
FINE PARTICLE PRODUCTION DEVICE AND FINE PARTICLE PRODUCTION METHOD
Provided is a fine particle production apparatus and a fine particle production method capable of easily obtaining surface treated fine particles. The fine particle production apparatus produces fine particles using feedstock by means of a gas-phase process. The apparatus includes a treatment section configured to transform the feedstock into a mixture in a gas phase state by means of the gas-phase process, a feedstock supply section configured to supply the feedstock to the treatment section, a cooling section configured to cool the mixture in a gas phase state in the treatment section using a quenching gas containing an inert gas, and a supply section configured to supply a surface treating agent to fine particle bodies in a temperature region in which the surface treating agent is not denatured, the fine particle bodies being produced by cooling the mixture in the gas phase state with the quenching gas.
Composite phosphate coatings
A method for providing composite phosphate conversion crystal coating, including the steps of: mixing powdered materials with metal oxide particles, thereby providing a composite metal oxide powder including particles of at least one additional powdered material, the at least one additional powdered material providing additional functionality to the phosphate conversion crystal coating; pretreating a substrate by depositing particles of the composite metal oxide powder on the substrate; treating the substrate with a phosphate coating solution, resulting in the composite phosphate conversion crystal coating forming on the substrate which contains fixed particles of the at least one additional powdered material.
Composite phosphate coatings
A method for providing composite phosphate conversion crystal coating, including the steps of: mixing powdered materials with metal oxide particles, thereby providing a composite metal oxide powder including particles of at least one additional powdered material, the at least one additional powdered material providing additional functionality to the phosphate conversion crystal coating; pretreating a substrate by depositing particles of the composite metal oxide powder on the substrate; treating the substrate with a phosphate coating solution, resulting in the composite phosphate conversion crystal coating forming on the substrate which contains fixed particles of the at least one additional powdered material.
E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.